

FOR IMMEDIATE RELEASE

AMNEAL LAUNCHES FLUOCINOLONE ACETONIDE FAMILY FOR SKIN AND EAR CARE

Generic maker expands into dermatology with three first-to-market offerings

Bridgewater, NJ (USA), November 21, 2011 – Amneal Pharmaceuticals, LLC is pleased to announce its new Fluocinolone Acetonide 0.01% Oil line of prescription ear drops, body oil and scalp oil, all first-to-market generics and the company's first topicals.

The Amneal generics are all fragrance-free, AT-rated, therapeutically equivalent alternatives to the otic and topical corticosteroids DermOtic® ear drops and Derma-Smothe/FS® body and scalp oils (registered trademarks of Hill Dermaceuticals, Inc.). Annual U.S. sales of Fluocinolone Acetonide 0.01% Oil are \$22 million according to June 2011 IMS Health market data.

The Amneal Fluocinolone Acetonide line is unscented for comfortable use by patients with sensitivities. Fluocinolone Acetonide is packaged in unit-of-use cartons complete with required accessories. The ear drops come in a 1 fl oz/30 mL bottle with pipette. The scalp oil is sold in 4 fl oz/118 mL size with two shower caps and convenient pop-up pour cap. The body oil also comes in a 4 fl oz/118 mL bottle with the extra pour cap.

“This is an exciting enhancement to Amneal's ever-broadening product portfolio, the addition of our first line of topicals,” states Chirag Patel, Amneal's president. “Topicals and dermatology products are two of our product-development focus areas, and this line impacts both,” he added.

Amneal's Fluocinolone Acetonide scalp oil, body oil and ear drops are now shipping and available through wholesalers-distributors as well as directly to the trade. The finished dosage forms are manufactured in the company's fully cGMP-compliant Branchburg, NJ production facility.

Amneal Pharmaceuticals, LLC, with principal offices in Bridgewater, NJ, is a U.S.-based firm that develops, manufactures and distributes generic pharmaceuticals regulated and approved by the U.S. FDA. Known as “Generic's New Generation”, the company utilizes its newly expanded R&D and manufacturing capabilities to conceive breakthrough developments with lasting impact for a robust product pipeline. Rapid ANDA approvals and diverse product acquisitions are key to Amneal's aggressive growth strategy, as is the company's strong commitment to deep customer relationships and maximum value creation. Amneal delivers high-quality products, superior service levels and dynamic value throughout the pharmaceutical industry. For more information, visit www.amneal.com.

###

CONTACT:

Jim Luce
Executive Vice President, Sales & Marketing
Amneal Pharmaceuticals, LLC
Direct: 949-610-8018
Fax: 949-610-8218
E-mail: jim@amneal.com
www.amneal.com
620 Newport Center Drive, 14th Floor
Newport Beach, California 92660